University of Birmingham Apixaban compared to heparin/vitamin K antagonist in patients with atrial fibrillation scheduled for cardioversion

Aim The primary objective was to compare apixaban to heparin/vitamin K antagonist (VKA) in patients with atrial fibrillation (AF) and <_48 h anticoagulation prior to randomization undergoing cardioversion. ...................................................................................................................................................................................................

[1]  G. Lip,et al.  Edoxaban versus enoxaparin–warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial , 2016, The Lancet.

[2]  P. Kirchhof,et al.  2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. , 2016, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[3]  P. Kirchhof,et al.  Apixaban compared with parenteral heparin and/or vitamin K antagonist in patients with nonvalvular atrial fibrillation undergoing cardioversion: Rationale and design of the EMANATE trial. , 2016, American heart journal.

[4]  G. Lip,et al.  Left atrial thrombus resolution in atrial fibrillation or flutter: Results of a prospective study with rivaroxaban (X-TRA) and a retrospective observational registry providing baseline data (CLOT-AF). , 2016, American heart journal.

[5]  R. de Caterina,et al.  Cardioversion of Atrial Fibrillation in ENGAGE AF‐TIMI 48 , 2016, Clinical cardiology.

[6]  S. Schulman,et al.  Definition of clinically relevant non‐major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non‐surgical patients: communication from the SSC of the ISTH , 2015, Journal of thrombosis and haemostasis : JTH.

[7]  Eric E. Smith,et al.  2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards). , 2015, Circulation.

[8]  A. Camm,et al.  Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation. , 2014, European heart journal.

[9]  Jun Zhu,et al.  Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation). , 2014, Journal of the American College of Cardiology.

[10]  Hugh Calkins,et al.  2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. , 2014, Journal of the American College of Cardiology.

[11]  Theresa M. Beckie,et al.  Council on Cardiovascular and Stroke Nursing. , 2014, The Journal of cardiovascular nursing.

[12]  Mary G. George,et al.  An Updated Definition of Stroke for the 21st Century: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association , 2013, Stroke.

[13]  G. Breithardt,et al.  Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial. , 2013, Journal of the American College of Cardiology.

[14]  D. Singer,et al.  Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. , 2012, Chest.

[15]  D. Atar,et al.  Apixaban versus warfarin in patients with atrial fibrillation. , 2011, The New England journal of medicine.

[16]  S. Yusuf,et al.  Dabigatran Versus Warfarin in Patients With Atrial Fibrillation: An Analysis of Patients Undergoing Cardioversion , 2010, Circulation.

[17]  S. Schulman,et al.  Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patients , 2005, Journal of thrombosis and haemostasis : JTH.

[18]  J. Mayet,et al.  Anticoagulation for cardioversion of atrial fibrillation. , 2002, Minerva cardioangiologica.

[19]  F. Loop,et al.  Role of prophylactic anticoagulation for direct current cardioversion in patients with atrial fibrillation or atrial flutter. , 1992, Journal of the American College of Cardiology.

[20]  O. Orning,et al.  The efficacy of anticoagulant therapy in preventing embolism related to D.C. electrical conversion of atrial fibrillation. , 1969, The American journal of cardiology.

[21]  Rimm,et al.  Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. , 2001, The New England journal of medicine.